|
1
|
Gospodarowicz MK, Sutcliffe SB, Brown TC,
Chua T and Bush RS: Patterns of disease in localized extranodal
lymphomas. J Clin Oncol. 5:875–880. 1987.PubMed/NCBI
|
|
2
|
Zouhair A, Herrmann E, Ugurluer G, Gaye
PM, Mirimanoff RO and Ozsahin M: Primary testicular lymphoma. Swiss
Med Wkly. 140:w130762010.
|
|
3
|
Eskey CJ, Whitman GJ and Chew FS:
Malignant lymphoma of the testis. AJR Am J Roentgenol. 169:8221997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gundrum JD, Mathiason MA, Moore DB and Go
RS: Primary testicular diffuse large B-cell lymphoma: a
population-based study on the incidence, natural history, and
survival comparison with primary nodal counterpart before and after
the introduction of rituximab. J Clin Oncol. 27:5227–5232. 2009.
View Article : Google Scholar
|
|
5
|
Møller MB, d’Amore F and Christensen BE:
Testicular lymphoma: a population-based study of incidence,
clinicopathological correlations and prognosis. The Danish Lymphoma
Study Group, LYFO. Eur J Cancer. 30A:1760–1764. 1994.PubMed/NCBI
|
|
6
|
Horne MJ and Adeniran AJ: Primary diffuse
large B-cell lymphoma of the testis. Arch Pathol Lab Med.
135:1363–1367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zucca E, Conconi A, Mughal TI, Sarris AH,
Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, et
al; International Extranodal Lymphoma Study Group. Patterns of
outcome and prognostic factors in primary large-cell lymphoma of
the testis in a survey by the International Extranodal Lymphoma
Study Group. J Clin Oncol. 21:20–27. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tepperman BS, Gospodarowicz MK, Bush RS
and Brown TC: Non-Hodgkin lymphoma of the testis. Radiology.
142:203–208. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shahab N and Doll DC: Testicular lymphoma.
Semin Oncol. 26:259–269. 1999.
|
|
10
|
Rosenwald A, Wright G, Chan WC, Connors
JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland
EB, Giltnane JM, et al; Lymphoma/Leukemia Molecular Profiling
Project. The use of molecular profiling to predict survival after
chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med.
346:1937–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosenwald A and Staudt LM: Gene expression
profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 44(Suppl
3): S41–S47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Z, Du Z, Chen J, Chen Z, Bao Y and
Tang F: Prognostic evaluation of immunohistochemical profiles in
diffuse large B-cell lymphoma: a Chinese study. Med Oncol.
28:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr
SS, Orazi A and Ulbright TM: Primary testicular diffuse large
B-cell lymphoma belongs to the nongerminal center B-cell-like
subgroup: A study of 18 cases. Mod Pathol. 19:1521–1527. 2006.
View Article : Google Scholar
|
|
14
|
Li D, Xie P and Mi C: Primary testicular
diffuse large B-cell lymphoma shows an activated B-cell-like
phenotype. Pathol Res Pract. 15:611–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kemmerling R, Stintzing S, Mühlmann J,
Dietze O and Neureiter D: Primary testicular lymphoma: a strictly
homogeneous hematological disease? Oncol Rep. 23:1261–1267.
2010.PubMed/NCBI
|
|
16
|
Hasselblom S, Ridell B, Wedel H, Norrby K,
Sender Baum M and Ekman T: Testicular lymphoma - a retrospective,
population-based, clinical and immunohistochemical study. Acta
Oncol. 43:758–765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Booman M, Douwes J, Glas AM, Riemersma SA,
Jordanova ES, Kok K, Rosenwald A, de Jong D, Schuuring E and Kluin
PM: Mechanisms and effects of loss of human leukocyte antigen class
II expression in immune-privileged site-associated B-cell lymphoma.
Clin Cancer Res. 12:2698–2705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Riemersma SA, Jordanova ES, Schop RF,
Philippo K, Looijenga LH, Schuuring E and Kluin PM: Extensive
genetic alterations of the HLA region, including homozygous
deletions of HLA class II genes in B-cell lymphomas arising in
immune-privileged sites. Blood. 96:3569–3577. 2000.
|
|
19
|
Horstmann WG and Timens W: Lack of
adhesion molecules in testicular diffuse centroblastic and
immunoblastic B cell lymphomas as a contributory factor in
malignant behaviour. Virchows Arch. 429:83–90. 1996.PubMed/NCBI
|
|
20
|
Kawakami T, Okamoto K, Kataoka A, Koizumi
S, Iwaki H, Sugihara H, Reeve AE, Ogawa O and Okada Y: Multipoint
methylation analysis indicates a distinctive epigenetic phenotype
among testicular germ cell tumors and testicular malignant
lymphomas. Genes Chromosomes Cancer. 38:97–101. 2003. View Article : Google Scholar
|
|
21
|
Batistatou A, Scopa CD, Ravazoula P,
Nakanishi Y, Peschos D, Agnantis NJ, Hirohashi S and
Charalabopoulos KA: Involvement of dysadherin and E-cadherin in the
development of testicular tumours. Br J Cancer. 93:1382–1387. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazloom A, Fowler N, Medeiros LJ, Iyengar
P, Horace P and Dabaja BS: Outcome of patients with diffuse large
B-cell lymphoma of the testis by era of treatment: the M. D.
Anderson Cancer Center experience. Leuk Lymphoma. 51:1217–1224.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi H, Tomita N, Yokoyama M, Tsunoda
S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K and
Ishigatsubo Y: Prognostic impact of extranodal involvement in
diffuse large B-cell lymphoma in the rituximab era. Cancer.
118:4166–4172. 2012. View Article : Google Scholar : PubMed/NCBI
|
